The funds will be used to complete the Early Feasibility Study (EFS) and advance towards a pivotal study approval. Laplace's technology focuses on developing a transcatheter tricuspid valve that offers a minimally invasive treatment option for patients with Tricuspid Regurgitation (TR), aiming to improve quality of life without the need for open-heart surgery.
The company has treated 22 patients in the U.S. as part of their EFS, with positive outcomes. Ned Scheetz, Founding Managing Partner at Aphelion Capital, has joined the company's Board of Directors. The device is currently in the development phase and has not yet received FDA approval.